Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05054088 · ClinicalTrials.gov registry record
ImmuneSense COVID-19 Variant Study
A clinical trial, sponsored by Adaptive Biotechnologies.
- Completed
- Registry status
- 203
- Enrollment target
NCT05054088: Completed study, sponsored by Adaptive Biotechnologies.
NCT05054088 is a clinical trial that has completed, run by Adaptive Biotechnologies. The registered enrollment target is 203 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05054088 has completed, sponsored by Adaptive Biotechnologies.
- COMPLETED
- Registry status
- 203 participants
- Enrollment target
Study Summary
This study will assess the clinical performance of the T-Detect™ COVID test to identify an immune response to SARS-CoV-2 infection in the setting of multiple circulating variants of the SARS-CoV-2 virus. Performance may vary depending on the variants circulating at the time of testing, including newly emerging strains of SARS-CoV-2 and their prevalence, which changes over time.
Primary Outcome
To determine the positive percent agreement (PPA) of the T-Detect™ COVID test with SARS-CoV-2 RT-PCR testing in populations having multiple circulating SARS-CoV-2 variant strains. The primary endpoint is the positive percent agreement (PPA) of the T-Detect™ COVID test with SARS-CoV-2 RT-PCR testing.
Interventions
- DEVICE T-Detect COVID test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 203 participants |
| Start Date | 2021-10-12 |
| Est. Completion | 2022-07-28 |
What the finished NCT05054088 record still lists
NCT05054088 is an observational study that tracks outcomes without assigning an intervention. The registered 203 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which T-Detect COVID test is the first listed.
NCT05054088 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05054088 about?
NCT05054088 is a clinical study titled "ImmuneSense COVID-19 Variant Study". This study will assess the clinical performance of the T-Detect™ COVID test to identify an immune response to SARS-CoV-2 infection in the setting of multiple circulating variants of the SARS-CoV-2 virus. Performance may vary depending on the variants circulating at the time of testing, including new...
What is the current status of trial NCT05054088?
This trial is currently completed. The enrollment target is 203 participants. The study started on 2021-10-12. Estimated completion is 2022-07-28.
What interventions are being tested in trial NCT05054088?
The interventions under investigation include: T-Detect COVID test (DEVICE).
Who is sponsoring clinical trial NCT05054088?
This trial is sponsored by Adaptive Biotechnologies, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05652686 · 203 participants · Phase 1
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- NCT06063122 · 203 participants · NA
Development of a Therapeutic Device to Improve Speech Sound Differentiation in Preterm Infants
- NCT07031245 · 203 participants · NA
Evidence-Based Quality Improvement to Reduce VA Primary Care Burnout
- NCT03481010 · 204 participants · NA
Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI